Aurora Cannabis Inc. (ACB) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
Key Financial Performance
Net Revenue $98 million, a 17% increase year-over-year, driven by 37% growth in global medical cannabis revenue and 85% growth in international revenue.
Adjusted Gross Margin 52%, an improvement of 1,000 basis points year-over-year, attributed to higher cannabis margins and favorable portfolio mix.
Adjusted EBITDA $10.8 million, a 209% increase from $3.5 million in the year-ago period, driven by higher net revenue and gross profit.
Free Cash Flow $9.2 million, a 42% increase from $6.5 million in the year-ago period, due to higher net revenue, improved contribution margin, favorable working capital changes, and lower capital expenditures.
Cash and Cash Equivalents $186 million, with no cannabis business debt, highlighting a strong balance sheet.
Medical Cannabis Net Revenue $64.8 million, a 37% increase year-over-year, driven by 85% growth in international markets and strong contributions from Canadian medical cannabis.
Medical Cannabis Adjusted Gross Margin 69%, up from 67% year-over-year, due to higher revenue from international markets, cost reductions, and improved production efficiency.
Consumer Cannabis Net Revenue $7.9 million, down from $11.5 million year-over-year, reflecting a strategic focus on higher-margin medical cannabis.
Consumer Cannabis Adjusted Gross Margin 33%, up from 20% year-over-year, due to sales of higher-margin products and cost improvements.
Plant Propagation Net Revenue $23.9 million, a 4% increase year-over-year, attributed to organic growth and expanded product offerings.
Plant Propagation Adjusted Gross Margin 6%, down from 18% year-over-year, due to nonrecurring inventory write-offs and surplus crops not sold.
Adjusted SG&A $37.4 million, a 19% increase year-over-year, driven by higher selling and distribution costs and costs from the acquisition of MedReleaf Australia.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New proprietary cultivars in Poland: Launched two new proprietary cultivars, marking the highest potency medical cannabis products in the country. These products are grown and manufactured in GMP-certified Canadian facilities.
Proprietary cultivar-specific inhalable cannabis extracts in the U.K.: Successfully launched a new product category, expanding the variety of high-quality medical cannabis available in the U.K.
International revenue growth: International revenue grew 85%, driven by strong performance in markets like Germany, Poland, and the U.K.
Market expansion in Australia and New Zealand: Australia is the second-largest market for Aurora, holding the #2 market share. New Zealand is identified as an emerging and growing market with high barriers to entry.
European market developments: Germany's descheduling in 2024 has led to increased patient registrations and higher prescription volumes. New markets like Switzerland and Austria are online, with positive developments in France, Turkey, and Ukraine.
Operational efficiencies: Lower production costs achieved through yield improvement, new cultivation technology, and strong third-party partnerships.
Adjusted gross margin improvement: Adjusted gross margin improved by 1,000 basis points to 52%, driven by higher cannabis margins and favorable portfolio mix.
Focus on high-margin medical cannabis: Medical cannabis now comprises 66% of net revenue, up from 57% in the previous year, with a focus on international markets.
Debt-free cannabis business: Aurora's cannabis business is completely debt-free, with $186 million in cash and no need for dilutive capital raises.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes in Germany: Potential regulatory changes in Germany could impact the company's growth plans, although no immediate significant rollback is expected.
Competitive Pressures in Australia: The Australian market is highly regulated and attracting new entrants, which could increase competition despite Aurora's strong positioning.
Temporary Headwinds in Poland: Regulatory changes in Poland previously impacted prescription volumes, though these headwinds have been resolved.
Nonrecurring Quality Issues in Plant Propagation: Inventory write-offs due to a nonrecurring quality issue and surplus crops not sold impacted margins in the plant propagation segment.
Incremental Costs from MedReleaf Australia Acquisition: Higher selling and distribution costs were incurred due to the acquisition of MedReleaf Australia, impacting SG&A expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Q2 2026 Revenue Growth: Consolidated net revenue is expected to increase year-over-year, driven primarily by 8% to 12% growth in the Global Medical Cannabis segment.
Plant Propagation Revenue: Expected to perform in line with traditional seasonal trends, with 25% to 35% of revenues normally earned in the second half of the calendar year.
Adjusted Gross Margins: Consolidated adjusted gross margins are expected to increase, driven primarily by 250 to 475 basis points growth in the cannabis business, with plant propagation adjusted gross margins expected to mostly perform in line with historical trends.
Adjusted EBITDA: Improvements in adjusted gross margins and higher global medical cannabis revenue should lead to continued strong positive adjusted EBITDA.
Free Cash Flow: While free cash flow is expected to be positive on an annual basis for the second consecutive year, there will be several significant cash outflows in line with historical trends that will impact free cash flow results in Q2 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the higher SG&A expenses in the quarter, and how should these expenses be viewed as a percentage of revenue going forward?
A:The higher SG&A expenses were attributed to variable costs associated with increased revenue, such as shipping and logistics, as well as M&A-related charges like financial services, inventory management, and ERP investments. Some of these costs are one-time. Management believes the current levels of adjusted SG&A are appropriate, but if revenue significantly increases, variable costs like distribution will also rise.
Q:Has there been an increase in competition in Europe, and how does Aurora view the margin structure evolving in the region?
A:Yes, there has been an increase in competition in Europe. Aurora views the margin structure as varying by country. In Poland, the market is consolidated with a few companies dominating, and it requires significant effort to enter. The U.K. market requires navigating a sophisticated distributor and clinic network. In Germany, maximizing margins requires having a local selling organization and connections with wholesalers, distributors, pharmacists, and telemedicine. While the market is more diluted, it remains challenging to maximize margins.
Q:What is the status of the Bevo liabilities and how does it impact the audit process?
A:The Bevo liabilities were moved to current due to a covenant breach related to not providing audited financials. This is an accounting treatment and does not impact Aurora's audit process. Bevo is working through the covenant issues, and management expects the matter to be resolved quickly.
Q:What is the guidance for 2Q adjusted EBITDA compared to 1Q?
A:Management expects adjusted EBITDA to remain positive and grow compared to 1Q.
Q:What is the timeline and potential impact of regulatory changes in Germany?
A:Regulatory changes in Germany are expected to be clarified by the end of the year (November or December). The impact is not expected to be as significant as in Poland due to Germany's broader and more mainstream medical cannabis system. Stricter regulations could benefit experienced companies like Aurora.
Q:Has Aurora returned to previous levels of volume and demand in Poland after regulatory changes?
A:Yes, Aurora has returned to previous levels of volume and demand in Poland. While the market may have slightly compressed, Aurora believes it has grown market share and continues to see success with high-quality and premium products.
Q:What is Aurora's current approach to supply chain and third-party suppliers?
A:Aurora produces 90% of its products in GMP or TGA-certified facilities and has invested in increasing yield, potency, and new cultivars. It also has a GMP facility in Germany. Aurora uses a third-party network for situational purchases of GMP and GACP products and has flexibility to expand cultivation if needed.
Q:Is Aurora considering vertical integration downstream in markets like Australia, Germany, and the U.K.?
A:Aurora has a clinic in Australia and works with clinics in other markets. Instead of owning downstream infrastructure, Aurora focuses on creating trade programs and alignment with third parties. This model has been effective for growth in these markets.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact percentage of SG&A expenses as a proportion of revenue going forward, instead offering general commentary on variable costs and revenue growth. Additionally, while discussing regulatory changes in Germany, the response lacked precise details on the potential impact and timeline, relying on broader statements about market preparedness and experience.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Capital
Executive Chairman
GMP facility
Research Division
basis point
cannabis market
cannabis plant
cannabis product
competitor
consumer cannabis
discussion
equivalent debt
headwind
improvement efficiency
increase contribution
leader cannabis
line trend
margin basis
margin market
market Germany
market cannabis
market share
operator
outlook
partnership
patient market
period cash
period increase
period margin
potency
prescription volume
priority
product offering
production
program
propagation line
propagation period
quality cannabis
quality product
value adjustment
ACB Transcript
Aurora Cannabis Inc. (ACB:CA) Q4 2026 Earnings Call Transcript
Neutral6-11
Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript
Unknown2-4
The earnings call summary suggests a mix of positive and neutral aspects. Positive factors include strong financial performance and strategic focus on profitable segments like global medical cannabis. However, uncertainties such as the exit from plant propagation, lack of specific timelines, and unclear management responses regarding revenue deceleration create a balanced outlook. The Q&A section did not reveal significant risks but highlighted strategic shifts and market exploration. Overall, the sentiment appears neutral due to the balanced nature of positive growth strategies and uncertainties in execution and market conditions.
Aurora Cannabis Inc. (ACB:CA) Q2 2026 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.
Aurora Cannabis Inc. (ACB) Q1 2026 Earnings Call Transcript
Positive8-6
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
ACB Slides
ACB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
